Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma Treatment with the triplet regimen of ...

Earlier this year, a Mayo Clinic retiree created KidneyCouch, an online resource for those with kidney cancer or chronic kidney disease.

Cancer fighting T-cells, the immune system's primary enforcers, are scarce in the rare kidney cancer called chromophobe renal cell carcinoma (ChRCC) and those that are present are indifferent to the ...

Clinical trial enrollment is vital for advancing renal cell carcinoma treatment, providing access to innovative therapies and potentially better care. The STELLAR-002 study evaluated zanzalintinib ...